Teleflex Incorporated (NYSE:TFX) – Equities researchers at Jefferies Group lowered their Q2 2018 earnings estimates for Teleflex in a research note issued to investors on Thursday. Jefferies Group analyst R. Denhoy now anticipates that the medical technology company will earn $2.31 per share for the quarter, down from their previous forecast of $2.33. Jefferies Group currently has a “Buy” rating and a $295.00 target price on the stock. Jefferies Group also issued estimates for Teleflex’s Q4 2018 earnings at $2.87 EPS.

TFX has been the topic of several other reports. Morgan Stanley lifted their target price on shares of Teleflex from $274.00 to $290.00 and gave the stock an “equal weight” rating in a research note on Friday. Leerink Swann raised shares of Teleflex from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $227.00 to $266.00 in a research note on Thursday, September 7th. Zacks Investment Research downgraded shares of Teleflex from a “buy” rating to a “hold” rating in a research note on Thursday, August 31st. Needham & Company LLC lifted their target price on shares of Teleflex from $237.00 to $285.00 and gave the stock a “buy” rating in a research note on Friday. Finally, KeyCorp reaffirmed a “hold” rating on shares of Teleflex in a research note on Wednesday, September 6th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the stock. Teleflex currently has an average rating of “Buy” and a consensus target price of $271.88.

ILLEGAL ACTIVITY WARNING: “Jefferies Group Analysts Reduce Earnings Estimates for Teleflex Incorporated (TFX)” was originally reported by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/11/06/jefferies-group-analysts-reduce-earnings-estimates-for-teleflex-incorporated-tfx.html.

Teleflex (NYSE:TFX) traded down $0.34 during mid-day trading on Monday, hitting $256.08. 34,285 shares of the company’s stock traded hands, compared to its average volume of 232,739. The stock has a market capitalization of $11,551.08, a PE ratio of 31.69, a P/E/G ratio of 2.47 and a beta of 1.05. The company has a debt-to-equity ratio of 0.88, a current ratio of 4.72 and a quick ratio of 3.70.

Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, November 2nd. The medical technology company reported $2.12 EPS for the quarter, topping the consensus estimate of $2.01 by $0.11. The firm had revenue of $534.70 million for the quarter, compared to the consensus estimate of $522.94 million. Teleflex had a net margin of 12.41% and a return on equity of 16.27%. The business’s revenue was up 17.3% compared to the same quarter last year. During the same period last year, the firm posted $1.80 earnings per share.

Hedge funds have recently made changes to their positions in the company. Toronto Dominion Bank boosted its holdings in shares of Teleflex by 14.5% during the 2nd quarter. Toronto Dominion Bank now owns 552 shares of the medical technology company’s stock valued at $115,000 after buying an additional 70 shares in the last quarter. Advisory Services Network LLC boosted its holdings in shares of Teleflex by 933.8% during the 2nd quarter. Advisory Services Network LLC now owns 827 shares of the medical technology company’s stock valued at $172,000 after buying an additional 747 shares in the last quarter. Cornerstone Capital Management Holdings LLC. bought a new stake in shares of Teleflex during the 2nd quarter valued at $175,000. Campbell & CO Investment Adviser LLC bought a new stake in shares of Teleflex during the 2nd quarter valued at $200,000. Finally, Calamos Advisors LLC bought a new stake in shares of Teleflex during the 2nd quarter valued at $206,000. Hedge funds and other institutional investors own 89.79% of the company’s stock.

In related news, Director Stephen K. M.D. Klasko sold 200 shares of Teleflex stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $241.88, for a total value of $48,376.00. Following the sale, the director now owns 8,080 shares in the company, valued at $1,954,390.40. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last quarter, insiders sold 600 shares of company stock worth $138,162. 2.39% of the stock is currently owned by company insiders.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Wednesday, November 15th will be issued a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 0.53%. The ex-dividend date of this dividend is Tuesday, November 14th. Teleflex’s dividend payout ratio (DPR) is currently 24.82%.

About Teleflex

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Earnings History and Estimates for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.